Is Boston Scientific Corporation a Good Stock to Buy Now?

Boston Scientific Corporation (BSX) is a good stock to buy according to a bullish thesis on Guardian Research's Substack. Despite a recent 17.5% selloff following Q4 2025 earnings, the company's growth trajectory is underpinned by multiple catalysts, including the adoption of Pulse Field Ablation, the emerging growth opportunity through left atrial appendage closure, and the Penumbra acquisition. BSX trades at a PEG ratio of 0.93, offering attractive growth at a discount compared to peers like Stryker and Intuitive Surgical. The stock is projected with a target price of $130, implying 71% upside, making it a strong buy across all time horizons.